Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . HHM A HUA MEDICINE 華 領 醫藥 ( Incorporated in the Cayman Islands with limited liability ) ( stock code : 2552 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2026 The Board is pleased to announce the unaudited consolidated results of the Group for the six months ended June 30 , 2026 , together with the comparative figures for the six months ended June 30 , 2025. Unless otherwise defined herein , capitalized terms used in this announcement shall have the same meaning as those defined in the Prospectus . BUSINESS HIGHLIGHTS In the first half of 2026 , we made solid progress in our transition to a commercialization - driven organization , with HuaTangNing ( *** ) entering a rapid scale - up phase and delivering strong sales growth . Expanded production scale and improved commercial operating efficiency led to a substantial reduction in our net loss . We sold approximately 3,055,000 packs of HuaTangNing ( *** ) in the first half of 2026 , up 73 % from 1,764,000 packs sold during the same period in 2025. This rapid sales growth trajectory is further supported by the maintenance of China's National Reimbursement Drug List ( NRDL ) price for the 2026 and 2027 calendar years . With continued expansion of our commercialization team and hospital coverage , revenue rose 74 % year - on - year to RMB378.9 million , reflecting the successful implementation of our in - house commercialization strategy . Increased production scale and efficiency led to significantly improved gross profit margins of 61.8 % for the period , which was significantly higher than the 54.2 % margin reported in the prior - year period . The ratio of selling expense to revenue moved into a stable range , standing at 33.5 % in the first half of 2026 , 4.0 percentage points higher compared with 29.5 % recorded in the same period in 2025 , comparable to the 33.6 % recorded for the full year of 2025 . Cash balances were RMB1,072.9 million as of June 30 , 2026 , which provides a strong foundation for our future R & D and commercialization initiatives .